Marker Therapeutics Says 'Strategic Prioritization of Clinical Programs With Focus on MT-601 in Patients With Lymphoma'
Marker Therapeutics Says 'Strategic Prioritization of Clinical Programs With Focus on MT-601 in Patients With Lymphoma'
Marker Therapeutics 表示 “以淋巴瘤患者的 MT-601 爲重點的臨床項目的戰略優先順序”
Marker Therapeutics Says 'Strategic Prioritization of Clinical Programs With Focus on MT-601 in Patients With Lymphoma'
Marker Therapeutics 表示 “以淋巴瘤患者的 MT-601 爲重點的臨床項目的戰略優先順序”
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。